74.63
+0.47
(0.63%)
After Hours: 74.42
-0.21
(-0.29%)
May 21, 4:11PM EDT
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 73.76 - 74.82 |
| 52 week | 51.20 - 75.67 |
| Open | 73.84 |
| Vol / Avg. | 1.51M/1.44M |
| Mkt cap | 183.38B |
| P/E | 19.08 |
| Div/yield | 2.43/3.25 |
| EPS | 3.91 |
| Shares | 2.46B |
| Beta | 0.57 |
| Inst. own | 10% |
Events
Jun 24, 2013
Novartis AG at JP Morgan Health Conference
Jun 18, 2013
Novartis AG at Citi European Healthcare Conference
Jun 11, 2013
Novartis AG at Vontobel Summer Conference
May 21, 2013
Novartis AG at UBS Nordic Investor Day
May 20, 2013
Novartis AG at Deutsche Bank dbAccess Asia Conference
May 8, 2013
Novartis AG at UBS Investor Day
Apr 4, 2013
Novartis AG at Kepler Seminar
Mar 26, 2013
Novartis AG at Exane BNP Paribas Healthcare Conference
Mar 11, 2013
Novartis AG at EBD BIO-Europe Spring
Mar 5, 2013
Novartis AG at Credit Suisse Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 17.05% | 16.71% |
| Operating margin | 20.39% | 20.00% |
| EBITD margin | - | 29.27% |
| Return on average assets | 7.92% | 7.96% |
| Return on average equity | 14.13% | 14.09% |
| Employees | 127,724 | - |
| Carbon Disclosure Rating | - | 91/100 |
Address
Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc.
Officers and directors
| Daniel L. Vasella M.D. | Chairman of the Board of Directors | |
| Joseph Jimenez | Chief Executive Officer, Member of the Executive Committee | |
| Ulrich Lehner | Vice Chairman of the Board of Directors, Non-Executive Director | |
| Jonathan R. Symonds | Chief Financial Officer, Member of the Executive Committee | |
| Felix R. Ehrat Ph.D. | Group General Counsel, Member of the Executive Committee | |
| Juergen Brokatzky-Geiger Ph.D. | Head Human Resources and Member of the Executive Committee | |
| Kevin J. Buehler | Member of the Executive Committee, Division Head, Alcon | |
| David R. Epstein | Member of the Executive Committee, Division Head, Pharmaceuticals | |
| Mark C. Fishman M.D. | Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR) | |
| Jeffrey George | Member of the Executive Committee and Division Head, Sandoz |